BBIO BridgeBio Pharma Forecast, Technical & Fundamental Analysis
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases... Show more
BBIO is expected to report earnings to fall 28.82% to -59 cents per share on July 30
Q2'26
Est.
$-0.60
Q1'26
Missed
by $0.16
Q4'25
Missed
by $0.28
Q3'25
Missed
by $0.07
Q2'25
Missed
by $0.20
The last earnings report on May 07 showed earnings per share of -83 cents, missing the estimate of -68 cents. With 481.20K shares outstanding, the current market capitalization sits at 16.46B.
A.I. Advisor
published General Information
General Information
a company which engages in developing transformative medicines to treat patients who suffer from mendelian diseases.
A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with AXON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then AXON could also see price increases.
BBIO in upward trend: price rose above 50-day moving average on June 24, 2026
BBIO moved above its 50-day moving average on June 24, 2026 date and that indicates a change from a downward trend to an upward trend. In of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on BBIO as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 10-day moving average for BBIO crossed bullishly above the 50-day moving average on June 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BBIO advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 206 cases where BBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for BBIO moved out of overbought territory on July 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where BBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BBIO broke above its upper Bollinger Band on July 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (22.722). P/E Ratio (0.000) is within average values for comparable stocks, (37.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.484). BBIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (27.933) is also within normal values, averaging (432.258).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
